Ewing sarcoma (ES) is the second most common type of primary bone malignancy, and retains a high propensity to metastasize; the prognosis of patients with disseminated disease is very poor, with an event-free survival rate of <20%. Current multimodality treatment for ES consists of combined chemotherapy before and concurrent with surgery and local radiotherapy for the involved bone. Cisplatin is one of the most widely used drugs for the treatment of bone tumors in children, but is not currently used in ES. We describe a child with multifocal ES, treated with a phase II trial including a single-drug window therapy, which displayed a dramatic response to 2 courses of cisplatin and had a favorable outcome.
*Department of Pediatric Hematology and Oncology, ARNAS Civico, Di Cristina and Benfratelli Hospital, Palermo
†Department of Pathology, Gaetano Pini Hospital
‡Department of Pediatric Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Supported by the parents’ Association “A.S.L.T.I.- Liberi di crescere” Onlus.
The authors declare no conflict of interest.
Reprints: Paolo D’Angelo, MD, U.O. di Oncoematologia Pediatrica, A.R.N.A.S. Ospedali Civico, Di Cristina e Benfratelli, Piazza Nicola Leotta 4, 90127 Palermo, Italy (e-mail: email@example.com).
Received December 3, 2012
Accepted February 20, 2013